156 related articles for article (PubMed ID: 25387724)
21. Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma.
Sevko A; Sade-Feldman M; Kanterman J; Michels T; Falk CS; Umansky L; Ramacher M; Kato M; Schadendorf D; Baniyash M; Umansky V
J Invest Dermatol; 2013 Jun; 133(6):1610-9. PubMed ID: 23223128
[TBL] [Abstract][Full Text] [Related]
22. The role of C5a in the innate immune response after experimental blunt chest trauma.
Flierl MA; Perl M; Rittirsch D; Bartl C; Schreiber H; Fleig V; Schlaf G; Liener U; Brueckner UB; Gebhard F; Huber-Lang MS
Shock; 2008 Jan; 29(1):25-31. PubMed ID: 17621257
[TBL] [Abstract][Full Text] [Related]
23. Impaired SNX9 Expression in Immune Cells during Chronic Inflammation: Prognostic and Diagnostic Implications.
Ish-Shalom E; Meirow Y; Sade-Feldman M; Kanterman J; Wang L; Mizrahi O; Klieger Y; Baniyash M
J Immunol; 2016 Jan; 196(1):156-67. PubMed ID: 26608909
[TBL] [Abstract][Full Text] [Related]
24. Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a.
Finch AM; Wong AK; Paczkowski NJ; Wadi SK; Craik DJ; Fairlie DP; Taylor SM
J Med Chem; 1999 Jun; 42(11):1965-74. PubMed ID: 10354404
[TBL] [Abstract][Full Text] [Related]
25. Plasma clearance of the human C5a anaphylatoxin by binding to leucocyte C5a receptors.
Oppermann M; Götze O
Immunology; 1994 Aug; 82(4):516-21. PubMed ID: 7835913
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity.
Mao Y; Sarhan D; Steven A; Seliger B; Kiessling R; Lundqvist A
Clin Cancer Res; 2014 Aug; 20(15):4096-106. PubMed ID: 24907113
[TBL] [Abstract][Full Text] [Related]
27. Sleep and circadian rhythm regulate circulating complement factors and immunoregulatory properties of C5a.
Reis ES; Lange T; Köhl G; Herrmann A; Tschulakow AV; Naujoks J; Born J; Köhl J
Brain Behav Immun; 2011 Oct; 25(7):1416-26. PubMed ID: 21539909
[TBL] [Abstract][Full Text] [Related]
28. The role of the complement anaphylatoxins in the recruitment of eosinophils.
DiScipio RG; Schraufstatter IU
Int Immunopharmacol; 2007 Dec; 7(14):1909-23. PubMed ID: 18039528
[TBL] [Abstract][Full Text] [Related]
29. Complement C5a: impact on the field of veterinary medicine.
Hezmee MN; Shiels IA; Rolfe BE; Mills PC
Vet J; 2012 Jun; 192(3):264-71. PubMed ID: 22277721
[TBL] [Abstract][Full Text] [Related]
30. Multiple Low Doses of 5-Fluorouracil Diminishes Immunosuppression by Myeloid Derived Suppressor Cells in Murine Melanoma Model.
Namdar A; Mirzaei HR; Jadidi-Niaragh F; Ashourpour M; Ajami M; Hadjati J; Rezaei A
Iran J Immunol; 2015 Sep; 12(3):176-87. PubMed ID: 26412636
[TBL] [Abstract][Full Text] [Related]
31. A key role of C5a/C5aR activation for the development of sepsis.
Riedemann NC; Guo RF; Ward PA
J Leukoc Biol; 2003 Dec; 74(6):966-70. PubMed ID: 12960283
[TBL] [Abstract][Full Text] [Related]
32. Pulp progenitor cell recruitment is selectively guided by a C5a gradient.
Chmilewsky F; Jeanneau C; Laurent P; Kirschfink M; About I
J Dent Res; 2013 Jun; 92(6):532-9. PubMed ID: 23603337
[TBL] [Abstract][Full Text] [Related]
33. Complement in asthma: sensitivity to activation and generation of C3a and C5a via the different complement pathways.
Wust SK; Blumenthal MN; Corazalla EO; Benson BA; Dalmasso AP
Transl Res; 2006 Oct; 148(4):157-63. PubMed ID: 17002917
[TBL] [Abstract][Full Text] [Related]
34. Active immunization against complement factor C5a: a new therapeutic approach for Alzheimer's disease.
Landlinger C; Oberleitner L; Gruber P; Noiges B; Yatsyk K; Santic R; Mandler M; Staffler G
J Neuroinflammation; 2015 Aug; 12():150. PubMed ID: 26275910
[TBL] [Abstract][Full Text] [Related]
35. Food intake regulation by central complement system.
Ohinata K; Yoshikawa M
Adv Exp Med Biol; 2008; 632():35-46. PubMed ID: 19025112
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of interleukin-6 synthesis in an animal model of septic shock by anti-C5a monoclonal antibodies.
Höpken U; Mohr M; Strüber A; Montz H; Burchardi H; Götze O; Oppermann M
Eur J Immunol; 1996 May; 26(5):1103-9. PubMed ID: 8647174
[TBL] [Abstract][Full Text] [Related]
37. HIV-1 induced generation of C5a attracts immature dendriticcells and promotes infection of autologous T cells.
Soederholm A; Bánki Z; Wilflingseder D; Gassner C; Zwirner J; López-Trascasa M; Falkensammer B; Dierich MP; Stoiber H
Eur J Immunol; 2007 Aug; 37(8):2156-63. PubMed ID: 17595678
[TBL] [Abstract][Full Text] [Related]
38. Enhancement of human cancer cell motility and invasiveness by anaphylatoxin C5a via aberrantly expressed C5a receptor (CD88).
Nitta H; Wada Y; Kawano Y; Murakami Y; Irie A; Taniguchi K; Kikuchi K; Yamada G; Suzuki K; Honda J; Wilson-Morifuji M; Araki N; Eto M; Baba H; Imamura T
Clin Cancer Res; 2013 Apr; 19(8):2004-13. PubMed ID: 23287562
[TBL] [Abstract][Full Text] [Related]
39. Signaling through C5aR is not involved in basal neurogenesis.
Bogestål YR; Barnum SR; Smith PL; Mattisson V; Pekny M; Pekna M
J Neurosci Res; 2007 Oct; 85(13):2892-7. PubMed ID: 17551982
[TBL] [Abstract][Full Text] [Related]
40. The effect of complement C5a on mitochondrial functions of PC12 cells.
Martinus RD; Cook CJ
Neuroreport; 2011 Aug; 22(12):581-5. PubMed ID: 21734613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
